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fasalazine, Multi-Matrix System mesalamine [MMX], balsalazide disodium, mesa-
lamine delayed release [MDR]) during 2007-2011. Patients were continuously en-
rolled in the 6-month pre- and 12-month post-initiation period. 5-ASA treatment
persistence and adherence according to the initial prescription filled (index medi-
cation) were compared. Persistence was defined as the duration between initiation
and discontinuation of therapy with a permissible gap 60 days, and analyzed
using Kaplan-Meier survival analysis. Persistence rates at month 12 were calcu-
lated. Adherence was measured by medication possession ratio (MPR) for index
drug, and proportion of days covered (PDC) for any 5-ASA. Analysis of covariance
was used to compare MPR and PDC across index medication. Covariates included
age, gender, insurance, residential region, comorbidities at index date, and use of
immunosuppressive/biologic agents, rectal form of 5-ASA and access to specialist
care post 12-month index date. RESULTS: A total of 5245 patients met selection
criteria, 59% were on MDR, 17% MMX, 13% sulfasalazine, and 11% balsalazide. The
median persistence days ranged from 151 [sulfasalazine] to 221 [MMX] days,
P0.001). Persistence rates at month 12 was highest for MMX (28%) compared to
other 5-ASAs (24% MDR, 23% balsalazide, and 20% sulfasalazine, respectively,
logrank P0.001). Mean adjusted MPR/PDC  standard error was significantly
higher in the patients on MMX (0.480.02/0.530.02) than that of patients on other
5-ASAs (0.430.01/0.500.01 [MDR], 0.430.02/0.490.02 [balsalazide], and
0.390.02/0.470.02 [sulfasalazine], P0.01/P0.04). CONCLUSIONS: Patients on
once-daily MMX were significantly more persistent and adherent with UC treat-
ment than those on other 5-ASA index drugs although persistence and adherence
with oral 5-ASAs in UC patients were suboptimal.
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OBJECTIVES: Our previous study suggested that Taiwan’s drug price adjustments
result in prescription switching from cheaper angiotensin-converting enzyme in-
hibitors (ACEIs) to expensive angiotensin receptor blockers (ARBs), demonstrated
by a macro level data that showed a decrease use in ACEIs and an increase use in
ARBs after policy implementation and by a long-term increasing trend observed in
annual prevalent ARB users that exceeded the cumulative incident ARB users. This
study uses individual patient level data to examine the proportions of prescription
switching from ACEIs to ARBs among the prevalent ARB users. METHODS: We
identified 82,447 patients treated with ARBs between Feb 1998 and Dec 2008 from
Taiwan’s Longitudinal Health Insurance Database (LHID2005). We examined the
monthly prevalent users of ARBs (from 2/1998 - 12/2008), the incident users of ARBs
(who receive ARBs first time in a givenmonth fromFeb 1998 to Dec 2008 and did not
receive ACEIs or ARBs in the preceding months from 1997 to 2008), and the ACEIs-
to-ARBs switchers (who used ARBs in a given month and used ACEIs or both drugs
[ACEIs in combinationwith ARBs] in lastmonth during 2/1998 - 12/2008). RESULTS:
The number of monthly prevalent ARB users increased from 4 to 32,292 from Fe-
burary 1998 to December 2008. The growth of ARB prevalent users was mainly
contributed by the incident ARB users and the ACEIs-to-ARBs switchers. The num-
ber of monthly incident ARB users increased from 2 to 562 and that of monthly
ACEIs-to-ARBs switchers increased from 1 to 477 from February 1998 to December
2008. The number of ACEIs-to-ARBs switchers exceeds that of incident ARB users
(averagemonthly ratio of the former to the latter is 1.25). CONCLUSIONS: Prescrip-
tion switching from cheaper ACEIs to expensive ARBs based on individual patient
level data is evident. Policy makers should be aware of this problem.
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OBJECTIVES: To evaluate the extent towhich racial and ethnic disparities in health
care utilization persist longitudinally. METHODS: We analyzed data from 2008 to
2010 National Health Interview Survey (NHIS) in the United States to examine
insurance status and utilization of health care based on race/ethnicity (non-His-
panic White, Hispanic White, Black, Asian, and others). We used two outcome
measures to define utilization of health care: at least one physician visit every two
weeks, and the average number of physician visits every twoweeks.We performed
multiple linear regression and logistic regression with sampling weight adjust-
ments for data analysis, stratified by dichotomous insurance status. Survey re-
spondents with private or public insurance or both were considered insured; oth-
erwise uninsured. All analyses were adjusted for age, education, gender, income-
to-poverty ratio, self-reported health status, and activity limitation. RESULTS:
Overall, insured rates decreased from 2008 to 2010 and the decreasing rate was
significantly associated with race/ethnicity (p0.01). Particularly, Asian had a
faster decreasing rate comparedwith non-Hispanicwhite (p0.05). The probability
of having at least one physician visit every two weeks for insured adults slightly
increased during 2008 and 2010, and was not significantly associated with race/
ethnicity. However, insured HispanicWhite and Asian Americans were still signif-
icantly less likely to have at least one physician visit every two weeks in compar-
ison to non-HispanicWhite (p0.05). The average number of physician visits every
two weeks for insured adults was significantly associated with year and race/eth-
nicity (p0.01). Both outcome measures did not significantly change from 2008 to
2010 for uninsured adults. CONCLUSIONS: Reducing racial and ethnic disparities is
an important priority in the United States. The results from NHIS show such dis-
parities in health care utilization persist regardless of insurance status. More stud-
ies are needed to identify other factors associated with such disparities.
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OBJECTIVES: To identify the rate of patient’s prescription filling in outpatient
health care departments in Indonesia, and to examine its related factor.
METHODS: Secondary data from the 4thWave Indonesia Family Life Survey (IFLS,
RAND Corp.) were used to obtain the Indonesia patients socio-economic charac-
teristics including their behavior on filling prescription in outpatient health care
departments. Factors related to prescription filling were identified from similar
studies such as educational level, economic status, geographical status (urban-
village, mainland-based), health insurance coverage, catastrophic health care
costs, satisfaction from health care received, andmorbidity (days of illness, illness
condition). Statistical analyses such as univariate, bivariate, andmultivariate anal-
yses were performed in a cross-sectional study to identify and to examine the
relationship between those factors with prescription filling rate. Meanwhile, inter-
action test also performed among variables in the multivariate model. RESULTS:
Six hundred forty-one respondent data were eligible and used for analysis pur-
poses. Results showed that 85,49% patients from outpatient health care depart-
ment filled their prescriptions. Bivariate analysis showed that factors related to the
prescription filling rate were educational level (p0,031), economic status
(p0,085), geographical status (p0,016 for urban-village, p0,000 for mainland-
based), and catastrophic outpatient health care costs (p0,060). Meanwhile, mul-
tivariate analyses showed that only geographical status (p 0,019 for urban-village)
was significant. In terms of geographical status, patients who lived in Java Island
had 1,6 times greater possibilities in prescription filling compared to patients who
lived in other islands. No interaction identified between variables in the last mul-
tivariate model. CONCLUSIONS: Prescription filling in the outpatient health care
department can be considered not optimum. Policy to enhance prescription filling
in outpatient health care department should put an emphasize on geographical
conditions of Indonesia which consists of thousand islands.
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OBJECTIVES: Providers of a new technology are increasingly obliged to give gov-
ernments an insight into related costs and benefits, and its value for money. This
necessitates the use of cost-effectiveness (CEA) and cost-utility data. A good health
policy, however,must not only aim to be efficient but should also guarantee equity.
METHODS: An analytic model has been developed to assess the ability to pay for
128 countries. The method introduces proportionality into pricing and reimburse-
ment decisions across and within Asia Pacific countries by taking into account
purchasing power paritymeasured at either the national or household level. Value-
based pricing techniques are used in combination with national income parame-
ters as defined in the Human Development Index together with health system
variables. The resulting non-linear equity curve is a graphic representation of a
price index calculated based on a country’s national income. The ratio of wealth
inversely reflects the theoretical discount rate that can be applied to each country
compared to a high income reference country. The steepest discounts are reserved
for the poorest countries, while for middle and high-income countries discounts
will decrease as the country’s wealth increases. RESULTS: The degree to which
‘equitable pricing’ offers a sustainable solution to the problem of access to medi-
cines depends on: the economic development status of a country, the value of a
particular medicine to its therapeutic class and the incidence of the disease, and
the extent to which segmentation can be applied. CONCLUSIONS: Equitable, dif-
ferentiated pricing can improve access to and affordability of medicines, particu-
larly in low- and middle-income countries. The method is relevant for the Asia
Pacific region confronted with disparity in the ability-to-pay (ATP) between coun-
tries, and between different population segments in the same country.
PHP41
RISK MANAGEMENT IN IRANIAN PHARMACEUTICAL COMPANIES TO ENSURE
ACCESSIBILITY AND QUALITY OF MEDICINES
Jaberidoost M, Abdollahiasl A, Farshchi A, Dinarvand R
Tehran University of Medical Sciences, Tehran, Iran
OBJECTIVES: Medicine Quality and accessibility are two of the main objectives of
health care systems. Pharmaceutical manufacturers have an important role to
meet these goals. But they are facedwith complicated environment and uncertain-
tieswhichcan affect ontheir performance and also accessibility andquality ofmed-
icines. Risk management is a new approach to assess and overcome these uncer-
tainties. In this study we have tried to identify, assess and make mitigation
strategies to manage risks which can affect on accessibility and quality of medi-
cines in three Iranian pharmaceutical companies.METHODS: First: The literatures
were reviewed for identification and categorization of potential risks. Second, a
semi-structured questionnaire was developed to get expert opinions about priori-
tization of risks andmitigations strategies. Third: the questionnaires were filled by
face to face interviewwith executive managers of three companies. RESULTS: Five
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main categories of risks were identified which could affect on accessibility and
quality named financial, supply, production, storage and logistic risks andin each
category there were several uncertainties. Inflation rate, exchange rate, incorrect
pricing, selection of suppliers, delay in shipment, policy issues, malfunction of
machineries, untrained personnel and inappropriate condition of storage and dis-
tribution are some of risks in different categories. All of these risks had direct or
indirect effect on quality or accessibility of medicines. CONCLUSIONS: Our study
offers risk assessment methodology as a scientific way for identification of uncer-
tainties which affect on quality and accessibility of medicines as two main objec-
tives of national drug policy and also it demonstrated some proper strategies to
mitigate them.
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OBJECTIVES: We examine how much of the cross-country drug price differences
can be explained by macroeconomic conditions (real GDP per capita, openness,
population, and corruption). METHODS: We use the Pricentric® dataset of drug
prices and analyze prices of 13 drug packs across 32 countries at various pack levels
in 2009. The sample is selected by requiring each pack having observations for
more than 20 countries and each country having observations for more than 20
packs. We gather data on real GDP per capita, openness, and population from the
PennWorld Table, and the Corruption Perceptions Index by Transparency Interna-
tional. The analysis has two parts. First, for each drug pack, we regress the log
prices (ex-factory, public, etc) on the four macroeconomic variables. Second, to
achieve better identification, we pool together all data and regress log prices on the
macroeconomic variables and drug fixed effects. RESULTS: For 6 of the 13 packs we
find that the four macroeconomic variables can explain the cross-country price
variations well (with R-squared over 8%). For the other 7 drugs the fit is worse, but
the signs of the coefficients among the 13 packs are in general consistent. The
pooled regression shows the same conclusion that the macroeconomic variables
have strong explanatory power. For thewhole sample, a 1% increase in real GDPper
capita correlates with a 0.15% increase in drug price. Openness has little impact,
while population has a small but significant positive association. A 1% increase in
the corruption index correlates with a 0.3% increase for all prices. CONCLUSIONS:
Controlling for drug fixed effects, macroeconomic variables show statistically sig-
nificant and economically large effects on drug pack prices. In particular, real GDP
per capita and corruption perceptions have large positive impacts suggesting drugs
cost more in either more developed countries or in more corrupted countries.
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OBJECTIVES: In 2008, GLOBOCAN estimated 2.8 million new cases of cancer in
China, making up 22% of all global cases. Although the Chinese government has
initiated a number of reforms to improve patient care, oncology drug access re-
mains a significant issue with medicines not being on national lists of essential or
reimbursed drugs. In China, manufacturers often set the price of oncology drugs
free of government mandates as these are not reimbursed. In contrast, in markets
where governments fund cancer treatment (South Korea, Japan, Taiwan), all med-
icines are assessed and undergo price setting/negotiation. Given these dynamics
and discussion by pharma companies to price medicines more in line with afford-
ability, this research explores the price differences for oncology agents across dif-
ferent types of markets taking into account the purchasing power parity and level
of patient access. METHODS: Review current prices of selected oncology agents
and the level of patient access across the Asian markets. Compare uptake of drugs
and identify drivers for access and uptake. Analyze prices relative to purchasing
power parity and compare to US& EU. RESULTS:The price differential across Asian
markets is correlated with lack of reimbursement, i.e., higher prices in countries
where there is no likelihood of reimbursement. In contrast, in countries where
these drugs are reimbursed, prices are tightly controlled and subject to regular
price cuts. Affordability remains the major challenge for access to cancer drugs.
CONCLUSIONS: Currently, innovative cancer drugs are outside the reach of most
Chinese as drug prices are some of the highest in the world. As the government
aims to reimbursemore oncology therapies, it will need to agree withmanufactur-
ers on price levels. Asianmarkets with ability to secure patient access tomedicines
at regulated prices can be useful models for China as the government looks to
improve the system.
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OBJECTIVES:Ourmajor objective of the studywas to assess the budgetary outcome
of implementing the first Hospital Essential Medicines List (HEML) 2011 with a
revised purchase policy in a rural resource limited, district charity hospital in India.
HEML was also compared with national and World Health Organization (WHO)
EMLs. METHODS: Expenditure on medicines purchase for the year of 2010 was
compared for the year 2011 (after the first HEML and revised purchase policy).
Evaluations were done to compare the number of medicines, dosage forms and
fixed drug combinations of tablets and injections. Microsoft Excel 2007 was used to
process the results. RESULTS: There was approximately 40 % reduction in the
money spent on medicines in 2011 when compared to 2010, which was approxi-
mately nine crores of Indian Rupees (approximately 1.7 Million US Dollars). The
number of medicines in 2010 was 1627, which was reduced to 424 in HEML 2011.
WHOEML 2011 has 350 and National Essential Drugs List (NEDL) 2011 of India has
348 medicines. While preparing the HEML, 31 tablets and 14 injections of two-drug
fixed combinationswere removed. The great reductionswere; 51 ointments to 9, 69
drops to 5, 11 paste to 0, 21 solutions to 3 and 14 creams to 1. The dosage forms
removed include elixir, insulin pen, gums, paste, paint, gargle, mouthwash.
CONCLUSIONS: New purchasing policy and implementation of HEML were the
crucial factors in the cost minimization, in our charitable hospital. The WHOEML
2011, NEML 2011 and the HEML 2011 were comparable with few exceptions. Health
care policy makers should note that, use of WHOEML and NEML with local experi-
ence makes implementation of HEML more practical in the countries with limited
professional resources.
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Compliance is an important factor for successful clinical management of schizo-
phrenia. Risperidone long-acting injection (RLAI) can improve compliance com-
pared to oral atypical anti-psychotics and several studies found the use of RLAIwas
associated with reduced hospitalization. RLAI was introduced to Japanese practice
from June 2009 and is currently only available atypical anti-psychotic depot
medication. OBJECTIVES: To assess the impact of RLAI use on hospitalization as a
proxy of relapse in daily practice among Japanese patients with schizophrenia.
METHODS: Mirror image comparison of psychiatric related hospitalization was
made for 6 months before (pre-RLAI) and 6 months after (post-RLAI) the initiation
of RLAI. The data source was commercially available health insurance claims da-
tabase (Japan Medical Data Center, Tokyo; January, 2009 to June, 2011). The inclu-
sion criteria were patients (20-59 years of age) who were diagnosed with schizo-
phrenia (ICD F20 to F29) and who had continuous enrollment of the Group health
insurance for 6 months before and 6 months after the initiation of RLAI. Patients
with long-term hospitalization (6 months) were excluded. Additionally, study
patients were restricted to have at least 3 month continuous treatment with RLAI.
In the analysis the initiation of RLAI during hospitalization contributed to pre-RLAI
hospitalization because previous treatment was considered as failure. RESULTS: A
total of 25 patients from 58 patients who were initiated on RLAI met the inclusion
criteria. Twenty patients started at outpatient visits and 21 patients continued the
RLAI treatment after 6 months. Mean dose was 33.5mg. The proportion of patients
requiring psychiatric hospitalization was changed from 28% to 8% between pre-
and post-initiating RLAI (P001). The total number of psychiatric hospitalization
was reduced by 82% (11 vs. 2, P0.02). CONCLUSIONS: Switching from oral anti-
psychotics to RLAImay impact on the reduction in hospitalization among Japanese
schizophrenic patients. Further investigation is necessary.
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OBJECTIVES: To estimate the annual prevalence, the related medical costs, and
health care resource utilization of patients diagnosed as herpes zoster (HZ) and
post-herpetic neuralgia (PHN), respectively, with different immune status in South
Korea.METHODS: This study is a retrospective analysis using the Korean National
Patients Sample 2009 database of the Health Insurance Review and Assessment
Service (HIRAK-NPS). Results of the sample databasewere extrapolated to the total
Korean population aged  40 years. HZ and PHN patients were identified from
diagnostic codes, and categorized into three subgroups based on the severity of
immune status; non-compromised, mild to moderate and severe status. Medical
costs included all HZ- or PHN-related costs incurred at medical facilities and med-
ication costs. RESULTS: The prevalence of HZ (or PHN) was 15.53 (or 2.13) per 1000
persons among those aged 40 years in South Korea. The annualmedical costs per
patient for HZ (or PHN)managementwere US$191 (or $177). The average number of
outpatient visits, emergency department visits and hospital admissions of HZ (or
PHN) patients were 3.75, 0.01, and 0.05 (4.44, 0.01, and 0.03) per annum, respec-
tively. With regard to the severity of immunodeficiency, patients with severe con-
ditions were related to higher prevalence rate, medical costs and health care
utilization. CONCLUSIONS: HZ and PHN cause considerable disease burden in
South Korea, especially among immunocompromised population. Considering
rapidly aging population and increasing prevalence of immunosuppressive condi-
tions, the disease burden is likely to increase. The findings of the present study can
serve as important baseline data for policy decision making to reduce the burden,
such as the development of a HZ vaccination recommendation.
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EXPENDITURE
Zhang J1, Ando G2, Bharath A2
A617V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 – A 6 8 1
